



This is a repository copy of *Validation of Surrogate Endpoints in Advanced Solid Tumors: Systematic Review of Statistical Methods, Results, and Implications for Policy Makers*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/98519/>

Version: Accepted Version

---

**Article:**

Ciani, O., Cantrell, A. [orcid.org/0000-0003-0040-9853](https://orcid.org/0000-0003-0040-9853), Davis, S. [orcid.org/0000-0002-6609-4287](https://orcid.org/0000-0002-6609-4287) et al. (6 more authors) (2014) Validation of Surrogate Endpoints in Advanced Solid Tumors: Systematic Review of Statistical Methods, Results, and Implications for Policy Makers. *International Journal of Technology Assessment in Health Care*, 30 (3). pp. 312-324. ISSN 0266-4623

<https://doi.org/10.1017/S0266462314000300>

---

This article has been published in a revised form in *International Journal of Technology Assessment in Health Care* [<https://doi.org/10.1017/S0266462314000300>]. This version is free to view and download for private research and study only. Not for re-distribution, re-sale or use in derivative works. © Cambridge University Press 2014.

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID  
TUMOURS: SYSTEMATIC REVIEW OF STATISTICAL METHODS,  
RESULTS, AND IMPLICATIONS FOR POLICY-MAKERS**

**Address for correspondence:**

Oriana Ciani, PhD Candidate

University of Exeter Medical School

Veysey Building, Salmon Pool Lane

Exeter, EX2 4SG, United Kingdom

Email: [oriana.ciani@pcmd.ac.uk](mailto:oriana.ciani@pcmd.ac.uk)

Phone: + 44 1392-726049

## **ABSTRACT**

**Objectives:** Licensing of, and coverage decisions on new therapies should rely on evidence from patient-relevant endpoints such as overall survival (OS). Nevertheless, evidence from surrogate endpoints may also be useful, as it may not only expedite the regulatory approval of new therapies but also inform coverage decisions. It is therefore essential that candidate surrogate endpoints be properly validated. However, there is no consensus on statistical methods for such validation and on how the evidence thus derived should be applied by policy-makers.

**Methods:** We review current statistical approaches to surrogate-endpoint validation based on meta-analysis in various advanced-tumour settings. We assessed the suitability of two surrogates (progression-free survival (PFS) and time-to-progression (TTP)) using three current validation frameworks: Elston and Taylor's framework, the German Institute of Quality and Efficiency in Health Care's (IQWiG) framework and the Biomarker-Surrogacy Evaluation Schema (BSES3).

**Results:** A wide variety of statistical methods have been used to assess surrogacy. The strength of the association between the two surrogates and OS was generally low. The level of evidence (observation-level vs. treatment-level) available varied considerably by cancer type, by evaluation tools and was not always consistent even within one specific cancer type.

**Conclusions:** Not in all solid tumours the treatment-level association between PFS or TTP and OS has been investigated. According to IQWiG's framework, only PFS achieved acceptable evidence of surrogacy in metastatic colorectal and ovarian cancer treated with cytotoxic agents. Our study emphasises the challenges of surrogate-endpoint validation and the importance of building consensus on the development of evaluation frameworks.

## BACKGROUND

Surrogate endpoints are intended to substitute for final patient-relevant endpoints that directly measure how patients feel, function or survive in clinical trials.<sup>1</sup> Evidence from surrogate endpoints may not only expedite the regulatory approval of new health technologies but also inform coverage and reimbursement decisions. In the United Kingdom, a number of recommendations of the National Institute for Health and Care Excellence (NICE) have been based on cost-effectiveness analyses entirely based on treatment effects derived from clinical trials assessing surrogate endpoints.<sup>2</sup> Moreover, this type of evidence may still be relied upon even when patient-relevant endpoints are available, for example in clinical trials that have terminated prematurely or for which data on the final endpoint are not fully mature. Nevertheless, relying on evidence from surrogate endpoints poses a serious challenge for decision makers, as several failures of candidate surrogate endpoints have been reported over the last decades<sup>3-5</sup>; such failures have arisen not only from discrepancies in the magnitude of treatment effects between surrogate and final endpoints,<sup>6</sup> but also in their directions.<sup>5</sup> Hence, in order for policy makers to use a surrogate endpoint with confidence, there must be a process of 'surrogate validation'.

The statistical validation of surrogate endpoints has been a major focus of research activity over the last two decades,<sup>7,8</sup> but no consensus exists with respect to the standards needed to identify valid surrogates. Nevertheless, two key tenets dominate current views on the issue, namely the 'correlation' and the 'meta-analytic' approaches.<sup>9,10</sup> According to these two tenets, the core goal of surrogate validation is to demonstrate a correlation between the surrogate and the final endpoint in the context of a clinical trial as well as between treatment effects on the surrogate and on the final endpoint within the context of a meta-analysis of randomised controlled trials (RCTs).<sup>10</sup> The uptake of surrogate validation methods in technology assessment and coverage decisions is limited,<sup>11</sup> a potential explanation being the lack of harmonisation of statistical techniques that should be used. Moreover, while decision tools have been proposed to assist policy makers in judging the strength of such

validation evidence for a candidate surrogate, there has been little or no empirical testing of these decision tools to date.<sup>2,7,12</sup>

Cancer trials are one of the areas in which surrogate endpoints have become most common.<sup>13-16</sup> Progression-free survival (PFS), measured as the time from randomisation to either documented tumour progression or death, is often used as primary endpoint in RCTs as a surrogate for overall survival (OS).<sup>17</sup> Tumour progression includes radiographic evidence<sup>18-20</sup> and, in some instances, non-radiographic criteria such as 'symptomatic progression' or 'clinical deterioration' determined by a clear, unequivocal worsening of the symptoms and signs of disease that are not evident on radiographic assessment.<sup>21</sup> Some trials use time-to-progression (TTP) rather than PFS, the difference being that in TTP, patients are censored at the time of death with no prior documentation of disease progression. Other surrogate endpoints have been adopted in oncology, the most common being tumour response rate. However, TTP and PFS are more often used in phase III clinical trials<sup>17</sup> and cost-effectiveness analyses of treatments for metastatic solid tumours,<sup>22</sup> whilst tumour response rate better served for this purpose in hematologic malignancies.<sup>16,23</sup>

In this paper, we review current statistical methods of surrogate-endpoint validation that use a meta-analytic framework. In addition, we assess the strength of evidence for PFS and TTP as surrogates for OS and test the application of current surrogate validation decision tools to the evidence base in a number of advanced solid tumours.

## **METHODS**

### **Study identification and selection**

Meta-analyses of RCTs quantifying the statistical association between PFS or TTP and OS in advanced solid tumours were sought. Conventional literature searches of electronic bibliographic databases returned a large number (>3,000) of references, and attempts to make the search more specific resulted in the exclusion of many of the papers already known to the authors. Therefore we used a 'citation pearl-growing' approach to study identification,<sup>24</sup> with backward and forward citation searching from an initial list of six papers

known to the authors.<sup>25-30</sup> The citation searches were conducted using Medline and the Science Citation Index in March 2012, and forward citation searching up until December 2012. Two reviewers independently screened titles and abstracts. We excluded conference abstracts, **letters to the editor**, papers reporting results from single trials, meta-analyses reporting treatment effects on PFS or TTP and OS without assessing an association between them, and descriptive reviews.<sup>17, 31, 32</sup> Meta-analyses that focused on oncology treatments with curative intent were also excluded, as PFS and TTP are not relevant endpoints in this case.<sup>33,34</sup>

### **Data extraction and analysis**

Three levels of data were extracted from included meta-analyses using standardised pro-formas: information on the general characteristics of each meta-analysis (authors and date of publication, criteria for inclusion of studies, number and nature of studies included, number of patients included, and type of tumour and interventions considered); details of the statistical methods reported to assess the association between surrogate and final endpoints, the results of these analyses, and each study authors' conclusions based on the results; and details of the literature search performed to identify included studies. Data were extracted by a single reviewer and checked by a second. Finally, we sought to analyse the suitability of PFS and TTP as surrogates for OS using established surrogate validation frameworks. Three surrogate validation frameworks identified by a recent review of surrogate-endpoint methods were applied to each meta-analysis;<sup>35</sup> they are outlined briefly below. **To ensure consistency, they were applied to each meta-analysis by a single reviewer and checked by a second reviewer, and discrepancies resolved with involvement of a third reviewer.**

#### *Elston and Taylor's framework*

In 1999, Bucher and colleagues<sup>36</sup> proposed a set of validity criteria to inform the use of an article measuring the effect of an intervention on surrogate endpoints in clinical practice.

These criteria were adapted by Elston and Taylor<sup>2</sup> into a three-level evidence hierarchy: Level 1, evidence demonstrating that treatment effects on the surrogate (i.e., the change on the surrogate endpoint of treatment vs. control arm) correspond to treatment effects on the final patient-relevant endpoint (from RCTs); Level 2, evidence demonstrating a consistent association between surrogate outcome and final patient-relevant outcome (from at least epidemiological/observational studies); Level 3, evidence of biological plausibility of a relationship between surrogate and final patient-relevant outcomes (from pathophysiologic studies and/or understanding of the disease process).

#### *German Institute of Quality and Efficiency in Health Care (IQWiG) framework*

In 2011, the Institute of Quality and Efficiency in Health Care (IQWiG), an independent health technology assessment (HTA) agency that assesses the benefits and harms of drug and non-drug technologies on behalf of the German Federal Joint Committee and the Federal Ministry of Health, published a framework for the validation of surrogate endpoints in oncology.<sup>12</sup> The IQWiG framework proposes that two levels of consideration are required in order to judge the suitability of a surrogate endpoint in the assessment of cancer therapy: the reliability of the evidence and the strength of evidence for surrogate validation. Reliability is measured as high, limited, moderate, or low on the basis of the following aspects: (1) application of a recognized approach described in the specialized statistical literature, (2) conduct of analyses to test the robustness and generalizability of results, (3) systematic compilation of data, (4) sufficient restriction of indications or degrees of disease severity and of interventions, and (5) clear definitions of the endpoints investigated. The strength-of-evidence criterion considers the degree of correlation of effects on the surrogate and the patient-relevant endpoint according to predefined thresholds (i.e., high correlation, when the lower limit of the 95% confidence interval for  $R \geq 0.85$ ; low correlation, when the upper limit of the 95% confidence interval for  $R \leq 0.7$ ; and medium correlation otherwise). Depending on the categorization produced by an algorithm that takes into account both levels of consideration, a conclusion about the validity of the surrogate endpoint is drawn and

expressed as proof, indication, hint or no proof of an effect on the patient-relevant endpoints as derived from an observed effect on the surrogate endpoint. While the IQWiG framework provides a list of elements that contribute to 'reliability', we needed to introduce a system of scoring that enabled us to categorise this dimension in a reproducible manner (e.g., a 'high' score required all contributing elements to be met).

### *Biomarker-Surrogacy Evaluation Schema (BSES3)*

The Biomarker-Surrogacy Evaluation Schema (BSES3)<sup>36</sup> is a revised version of a previous scheme (BSES),<sup>38</sup> proposed in 2010. The BSES3 validation framework consists of four domains: study design, target endpoint, statistical evaluation, and generalisability. Details of the elements that comprise these domains are shown in the online data supplement (Supplementary Table 1). Each domain is ranked from 0 to 3 and combined to determine an overall score (ranging from 0 to 12). A hierarchical scale of validity is attached to the overall score, with 'A' corresponding to highest validity (i.e., overall score 12) and 'F-' to lowest. The developers suggest that an overall score of 9 or above, equivalent to a category of 'A' or 'B', is required to identify a good level of evidence of surrogate validation.

## **RESULTS**

### **Characteristics of included meta-analyses**

Of the 758 papers identified by citation searching, 31 publications were included. Figure 1 summarises the selection process, whereas Table 1 presents a summary of the characteristics of the included meta-analyses. Details for each meta-analysis are provided in Supplementary Table 2. The majority of them (N=24, 77%) restricted their analyses to a single tumour type, although some reported separate analyses for two,<sup>26,29,39,40</sup> or more tumour types.<sup>25,41,42</sup> Two meta-analyses<sup>43,44</sup> of patients with glioblastoma multiforme were included; the poor median survival and the fact that metastases are seldom found in this disease suggest that PFS and OS would be important endpoints. The most frequent tumour



types examined were colorectal cancer,<sup>25-29,39-42,45-47</sup> non-small-cell lung cancer (NSCLC),<sup>25,29,41,48-52</sup> breast cancer,<sup>25,30,39,41,42,53-55</sup> and ovarian cancer.<sup>9,26,40-42,56,57</sup>

Eighteen meta-analyses were based on aggregate data, while 13 used individual patient data (IPD). In the aggregate-data meta-analyses, the number of included trials per meta-analysis ranged from 13 to 191 (median, 39) and the number of patients per meta-analysis ranged from approximately 4,300 to 44,000 (median, 15,850). For IPD meta-analyses, these numbers were lower, ranging from two to 27 trials (median, four) and 193 to 3,953 patients (median 1,158). Aggregate-data meta-analyses frequently reported using a systematic literature search to identify included studies (15/18, 84%) whereas none of the IPD meta-analyses stated so. The criteria used to select included trials varied markedly across meta-analyses. The scope of meta-analyses were determined by type of intervention (e.g., gefitinib or erlotinib monotherapy,<sup>49</sup>), line of therapy (e.g., first-line<sup>29,45,46,48,52</sup>), or other trial characteristics (e.g., sample size<sup>27,45,46</sup>).

### **Statistical methods to assess the association between surrogate and final endpoints**

A wide variety of differing methods to examine the association between surrogate and final endpoints were employed across the 31 meta-analyses. Two broad criteria may be used to summarise these statistical methods. The first criterion is the type of meta-analysis, as noted above (meta-analyses using aggregate data and those using IPD). The second criterion is the level of association reported: ten meta-analyses (32%) reported on the 'observation-level association' or Level-2 evidence<sup>2</sup> or 'individual-level surrogacy'<sup>10</sup>, i.e., the association between surrogate and final endpoints regardless of the treatment effect on each of the endpoints; 12 meta-analyses (39%) reported the 'treatment-level association' or Level-1 evidence<sup>2</sup> or 'trial-level surrogacy'<sup>10</sup>, i.e., the association between the treatment effect on the surrogate and the treatment effect on the final endpoint; and nine studies (29%) reported both levels of association. Combining these two criteria allowed for four core categorizations of the assessment and reporting of the association between PFS/TTP and OS: (1) meta-

analyses that reported an observation-level association based on aggregate data<sup>27,45,46,49,51,52,58</sup>, e.g., single-arm median PFS/TTP vs. median OS; (2) meta-analyses that reported an observation-level association based on IPD<sup>9,28,40,43,44,47,50,53,56,59-61</sup>, e.g., patients' TTP vs. survival time; (3) meta-analyses that reported a treatment-level association using aggregate data<sup>25,27,29,30,39,41,42,46,48,54,55,57,58,62</sup>, e.g., hazard ratio (HR) for PFS/TTP vs. HR for OS; and (4) meta-analyses that reported a treatment-level association using IPD<sup>9,26,28,40,47,53,59</sup>. An overview of the statistical methods used presented according to these four categorisations is provided in a **Supplementary technical note, with further details shown in Supplementary Table 2 and Supplementary Table 3.**

### **Assessment of the validity of PFS and TTP as surrogates for OS**

The main results of meta-analyses on the potential role of PFS or TTP as surrogates for OS are presented in Tables 2 and 3, respectively. The validity of these candidate surrogates was assessed according to the Elston and Taylor's, IQWiG, and BSES3 frameworks applied to each meta-analysis, grouped according to the tumour type. An extract of the original authors' conclusions on the surrogacy of PFS or TTP is also presented for each meta-analysis. The four most frequently evaluated advanced solid tumours were colorectal cancer, NSCLC, breast cancer, and ovarian cancer. While the available evidence consistently shows an association between treatment effects on PFS or TTP and treatment effect on OS (i.e., Level 1 evidence according to Elston and Taylor's framework) in metastatic colorectal cancer, the validity of these surrogate measures appear relatively low when rated by both the IQWiG and BSES3 frameworks (Tables 2 and 3). However, four studies<sup>26-28,47</sup> provide an 'indication' of an effect on the final endpoint given the effect observed on PFS, according to the IQWiG framework (Table 2). Nevertheless, as these analyses were limited to trials within a specific treatment setting (i.e., the comparison of fluorouracil (FU) plus leucovorin with either FU alone or with raltitrexed<sup>47</sup>) and did not provide evidence across different risk populations and drug-class mechanisms, they were scored down on the BSES3 framework. For advanced lung cancer, three meta-analyses<sup>49,50,61</sup> only reported observation-level

association between PFS and OS in NSCLC; in small-cell lung cancer, Foster et al.<sup>59</sup> reported high correlation ( $R^2_{\text{trial}} = 0.79$ ) between HR observed on PFS and OS (on the log scale), thus providing an 'indication' for an effect on OS having observed an effect on PFS according to the IQWiG framework (Table 2). TTP does not appear to be a good surrogate measure in advanced lung cancer according to any of the three frameworks (Table 3). In metastatic breast cancer, despite the moderate to high quality of the meta-analyses assessed<sup>42,53,55</sup>, PFS is not judged to be a valid surrogate for OS according to the three evaluation frameworks adopted (Table 2). However, Hackshaw and colleagues<sup>54</sup> reported a medium association between TTP and OS ( $R^2 = 0.56$ ) in trials of first-line chemotherapy, which provided a 'hint' for an effect on the final endpoint according to the IQWiG framework (Table 3). In metastatic ovarian cancer, three IPD meta-analyses, two related to PFS (Table 2),<sup>26,40</sup> and one to TTP<sup>9</sup> (Table 3) show an indication of an effect on OS drawn on the observation of an effect on the two surrogate endpoints, with  $R^2_{\text{trial}}$  ranging from 0.83 to 0.95. Nonetheless, as according to the BSES3 criteria (see Supplementary Table 1) they lack generalisability, these studies were scored down. The remaining six solid tumour types (renal, prostate, brain, gastric, head and neck, and pancreatic) were each assessed in one or two meta-analyses (Tables 2 and 3). Across these indications, the level of evidence was mixed and the strength was poor; moreover, the endpoints were not always clearly specified, therefore all scores for strength of surrogacy relationship were low in both the IQWiG and BSES3 frameworks (in brain and gastric cancer Level 2 was the highest level of evidence according to Elston and Taylor's framework).

## DISCUSSION

We sought to review the current statistical approaches to surrogate endpoint validation in advanced solid tumours, as well as to assess the suitability of PFS and TTP as surrogates for OS using currently available validation frameworks.<sup>35</sup> Our review included 31 meta-analyses (1,363 RCTs enrolling more than 290,000 patients) and showed that a variety of statistical methods have been used to examine the relationship between PFS or TTP and

OS. In addition, we observed a degree of variation in validity rating when using different validation frameworks across meta-analyses in general and even within a particular tumour type.

The various statistical methods used thus far in surrogacy research can be summarised in two broad categorisations. First, according to whether the assessment of the statistical association is made between the surrogate and final endpoint (observation-level association, which does not take treatment into account and is therefore an assessment of the prognostic role of the candidate surrogate), or between the treatment effects on both surrogate and final endpoints (treatment-level association, which assesses the predictive role of the candidate surrogate by taking treatment into account). Second, according to whether aggregate data or IPD were used. Observation-level association has been reported both using aggregate data and IPD, with different metrics used to quantify the correlation between endpoints (e.g., Spearman's  $\rho$  for median PFS versus median OS in the former<sup>27,45,46,51,58</sup> and  $R^2_{\text{individual}}$  in the latter<sup>9</sup>). In a number of cancer types, such as metastatic gastric cancer and glioblastoma multiforme, only the observation-level association has been investigated so far. This is acknowledged to be insufficient evidence to establish surrogacy for putative surrogate endpoints.<sup>10</sup> For most tumour types, including colorectal cancer, breast cancer, and NSCLC, both observational-level and treatment-level surrogacy has been investigated, with treatment-level surrogacy being assessed using both IPD and aggregate data. Although treatment-level associations were often reported using the common statistic of  $R^2_{\text{trial}}$ , this was calculated using different analytic approaches (e.g., meta-regression for aggregate data,<sup>27,29,30,41,42,45,46,55,62</sup> and hierarchical regression methods for IPD<sup>9,26,28,40,47,53,59</sup>).

There is little literature directly comparing statistical validation of surrogates using IPD compared with aggregate level data.<sup>28</sup> Buyse and colleagues have proposed IPD meta-analysis and calculation of both the  $R^2_{\text{individual}}$  and  $R^2_{\text{trial}}$  to be the gold standard approach to the statistical surrogate validation.<sup>10</sup> However, only 22% of the meta-analyses in this review met this criterion. Such a low proportion is in large part due to the practical challenges of conducting an IPD meta-analysis. Gathering, cleaning and formatting patient data from

across clinical trial centres involves substantial resources, as due to commercial or academic restrictions, IPD for some trials are not immediately available in the public domain. While regulatory agencies can require companies to make such data available, this is often not the case for HTA organizations or agencies with a coverage or reimbursement mandate. Hence, while an IPD meta-analytic approach remains the optimal statistical approach to surrogate validation, it is likely that meta-analyses of treatment-level associations reporting the  $R^2_{\text{trial}}$  or equivalent statistics will continue to be undertaken. There is often a lack of appreciation that the use of aggregate data entails a loss of information that may have a profound impact on the analyses performed, and their interpretation. For instance, several meta-analyses included in our review used the ratio of medians as a measure of treatment effects<sup>27,32,48,54,55</sup>. Such an approach could be seriously misleading if the time to event distributions were not exponential and, even if they were, the medians usually have wide confidence intervals and so their ratio is likely to be extremely unstable.<sup>63</sup> Few regression analyses make proper allowance for the estimation error,<sup>9,26,28,40,53</sup> other than through a weighting of the trials by their sample size. Regression analyses that ignore estimation errors are likely to underestimate the true relationship between the treatment effects on the surrogate and the final endpoint. The availability of IPD allows the association between the surrogate and the final endpoints to be modelled, which is theoretically preferable to looking only at the marginal association between the treatment effects on the two endpoints.<sup>9</sup>

### **Limitations of this study**

To the best of our knowledge, this is the first study to empirically test the application of current surrogate validation frameworks across a sample of meta-analyses in a disease area. On the other hand, our study has some limitations. First, as we were unable to use a conventional search strategy, we cannot claim to have identified all relevant meta-analyses. A more exhaustive search might have been feasible if we had narrowed our scope to a single tumour type. However, our aim was to keep the scope of the study broad and to identify a sufficient number of meta-analyses to assess a variety of statistical methods. **Our**

list of included meta-analyses appears indeed to be comprehensive when compared with recent reviews in the field.<sup>12,32</sup> Second, we have not formally appraised the overall quality of each meta-analysis. Given that the focus of the study was not to determine an unbiased estimate of the efficacy or safety of interventions, we believe that this decision was justified. However, to assess potential selection or publication bias, we noted if each included meta-analysis reported undertaking a formal literature search strategy to identify studies. In line with the findings of previous studies, we found that meta-analyses of aggregate data were more likely to undertake a literature search and include more studies than IPD meta-analyses.<sup>51</sup> Third, we have not attempted to replicate any of the analyses presented in the included meta-analyses. This might have been useful, as it would allow us to examine whether all of the assumptions made in the presented analyses are supported by the primary data and whether the conclusions change when all relevant trials are considered in a single analysis and after updating for more recently published trials. Fourth, the application of both the IQWiG and BSES3 evaluation frameworks involved an element of subjective judgement. In order to minimise potential assessment bias, the application of the frameworks undertaken was independently checked by a second reviewer and a third reviewer used to resolve disagreements in judgement of these two reviewers. All of them were HTA analysts with experience in the field of oncology. Finally, although survival is a definitive patient-relevant outcome in the case of most solid tumours, there may be problems with using of OS in the context of surrogate validation. Despite its primacy, OS has been claimed to be unsuitable in detecting treatment benefit in settings for which effective therapy is available after trial participation.<sup>64</sup> Because patients in oncology trials are often permitted to cross over from the control arm to the treatment arm or switch to other therapies due to lack of response or symptoms, the attribution of OS gain to initial treatment allocation may be confounded by these subsequent lines of therapy.<sup>65</sup>

## Implications for policy and practice

Surrogate validation studies also have important relevance for the assessment of the cost effectiveness of new treatments.<sup>66</sup> Using a reported relationship between OS and the surrogate, decision analysts can estimate the incremental cost per quality-adjusted life-year (QALY) based on the observed treatment effect on the surrogate.<sup>2</sup>

Our study has important implications for the use of surrogate outcomes in HTA and coverage/reimbursement policy decisions. In order to appropriately apply evidence of surrogate validation, policy makers need decision frameworks that help them do so. While the IQWiG and BSES3 frameworks are potentially useful tools for clinicians and health care decision makers, there are problems in their practical application. Both have elements that require subjective judgement. In addition, they require a high level of association to demonstrate surrogacy, i.e.,  $R^2_{\text{treatment}} \geq 0.60$  or  $R_{\text{treatment}} \geq 0.85$ , raising a query on the origins of such thresholds. With a small number of exceptions, we found the strength of the association between PFS or TTP and OS across meta-analyses to be consistently low (i.e.,  $R_{\text{treatment}} < 0.7$ ) across tumour types. Indeed, according to the IQWiG and BSES3 validation frameworks, the evidence available about surrogacy of PFS and TTP in metastatic cancer is still insufficient to guide policy. Moreover, we noted a degree of variation in validity rating of IQWiG and BSES3 frameworks across meta-analyses within a particular tumour type. For example, for PFS in colorectal cancer, four meta-analyses<sup>26-28,47</sup> showed an 'indication' of an effect on OS given an effect observed on the surrogates, however the highest level of evidence achieved according to BSES3 is C, well below the minimum acceptable level for a good surrogate. We believe that this variation probably reflects differences in the evidence within each meta-analysis due to differences in the precise patient population, definition and assessment of progression, drug therapy and comparator of included trials. Moreover, variation may also be due to differences in the statistical methods applied by each meta-analysis. Finally, the criteria considered by the two evaluation frameworks are different and in some cases opposite; for instance, BSES3 favours generalisability across populations and

drug-class mechanisms while the IQWiG framework gives precedence to restricted indications and therapies. Nonetheless, within each indication, different meta-analyses deal with overlapping evidence, and the underlying redundancy may have accounted for similar conclusions. **When considering conclusions across indications, our results support the need for a disease-specific approach to the validation of surrogate endpoints, with careful consideration of transferability of results from one disease to the other.**

The three evaluation tools used herein were developed through different processes: Elston and Taylor's framework was based on a guide for clinicians proposed by the Journal of the American Medical Association (JAMA) Evidence-Based Medicine Working Group; the algorithm for surrogate endpoints validation in oncology was developed at IQWiG after a systematic search of the literature by the Agency; whereas the BSES3's initial version originated from a literature review followed by a stakeholder workshop that evaluated it for applications in rheumatology.<sup>38</sup> We believe that the development of future surrogate validation tools would benefit from formal consensus methods. Further research is needed to examine the application of surrogate validation frameworks in the context of candidate surrogates both in oncology and other disease areas.

In conclusion, we found that the level of evidence available supporting a relationship between PFS or TTP and OS varies considerably by tumour type and is not always consistent even within one specific type. Overall, the strength of the association between PFS or TTP and OS was relatively low and only PFS in advanced colorectal and ovarian cancers treated with cytotoxic agents was found to be a valid surrogate endpoint according to one of the evaluation frameworks used. Our study emphasises the importance of building consensus on appropriate statistical techniques to examine surrogacy and on development of evaluation frameworks, not only in oncology but across all areas of medicine, across jurisdictions and scientific communities.



## REFERENCES

1. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. *Controlled clinical trials* 2001;22:485-502.
2. Elston J, Taylor RS. Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports. *International journal of technology assessment in health care* 2009;25:6-13.
3. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. *BMJ (Clinical research ed)* 2011;343:d7995-d.
4. Messerli FH, Bangalore S. ALTITUDE Trial and Dual RAS Blockade: The Alluring but Soft Science of the Surrogate End Point. *The American journal of medicine* 2013;126:e1-3.
5. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? *Annals of internal medicine* 1996;125:605-13.
6. Ciani O, Buyse M, Garside R, et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. *BMJ (Clinical research ed)* 2013;346:f457.
7. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. *Statistical Methods in Medical Research* 2008;17:303-40.
8. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. *Statistics in Medicine* 2006;25:183-203.
9. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. *Biostatistics* (Oxford, England) 2000;1:49-67.

10. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points--the challenge of statistical validation. *Nature reviews Clinical oncology* 2010;7:309-17.
11. Velasco Garrido M, Mangiapane S. Surrogate outcomes in health technology assessment: an international comparison. *International journal of technology assessment in health care* 2009;25:315-22.
12. IQWiG. Validity of surrogate endpoints in oncology. Executive Summary. Cologne, Germany: IQWiG; 2011. (Accessed January, 2013, at [https://www.iqwig.de/download/A10-05\\_Executive\\_Summary\\_v1-1\\_Surrogate\\_endpoints\\_in\\_oncology.pdf](https://www.iqwig.de/download/A10-05_Executive_Summary_v1-1_Surrogate_endpoints_in_oncology.pdf)).
13. Ellenberg S, Hamilton JM. Surrogate endpoints in clinical trials: cancer. *Statistics in Medicine* 1989;8:405-13.
14. Dunn BK, Akpa E. Biomarkers as surrogate endpoints in cancer trials. *Seminars in oncology nursing* 2012;28:99-108.
15. Berghmans T, Pasleau F, Paesmans M, et al. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2012;39:9-28.
16. Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. *International Journal of Clinical Oncology* 2009;14:102-11.
17. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:1958-62.
18. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2006;24:3245-51.

19. Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man. Methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. 2013. (Accessed January, 2013, at [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general\\_content\\_000406.jsp&mid=WC0b01ac0580034cf3](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000406.jsp&mid=WC0b01ac0580034cf3).)
20. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *European journal of cancer* 2009;45:228-47.
21. Dancey JE, Dodd LE, Ford R, et al. Recommendations for the assessment of progression in randomised cancer treatment trials. *European journal of cancer* 2009;45:281-9.
22. Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S. Methodological issues in the economic analysis of cancer treatments. *European journal of cancer* 2006;42(17):2867-75.
23. Sridhara R, Johnson JR, Justice R, et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. *Journal of the National Cancer Institute* 2010;102(4):230-43.
24. Hartley R, Keen, EM, Large, J, Tedd, LA. *Online Searching: Principles and Practice*. Epping, UK: BowkerSaur; 1990.
25. Bowater RJ, Bridge LJ, Lilford RJ. The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. *Cancer letters* 2008;262:48-53.
26. Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. *Pharmaceutical Statistics* 2006;5:173-86.
27. Chirila C, Odom D, Devercelli G, et al. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. *International journal of colorectal disease* 2012;27:623-34.

28. Green E, Yothers G, Sargent DJ. Surrogate endpoint validation: statistical elegance versus clinical relevance. *Statistical Methods in Medical Research* 2008;17:477-86.
29. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. *The lancet oncology* 2006;7:741-6.
30. Sherrill B, Amonkar M, Wu Y, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. *British journal of cancer* 2008;99:1572-8.
31. Buyse M. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. *Cancer journal* 2009;15:421-5.
32. Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. *OncoTargets and therapy* 2012;5:287-96.
33. Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2011;22:1392-403.
34. Tibaldi F, Barbosa FT, Molenberghs G. Modelling associations between time-to-event responses in pilot cancer clinical trials using a Plackett-Dale model. *Statistics in Medicine* 2004;23:2173-86.
35. EUnetHTA. Endpoints used in REA of pharmaceuticals - Surrogate Endpoints. In; 2013. (Accessed March, 2013, at <http://www.eunetha.eu/sites/5026.fedimbo.belgium.be/files/Surrogate%20Endpoints.pdf>)
36. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. *Evidence-Based*

- Medicine Working Group. *JAMA : the journal of the American Medical Association* 1999;282:771-8.
37. Lassere MN, Johnson KR, Schiff M, Rees D. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES). *BMC medical research methodology* 2012;12:27.
38. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. *The Journal of rheumatology* 2007;34:607-15.
39. Bowater RJ, Lilford PE, Lilford RJ. Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer. *International journal of technology assessment in health care* 2011;27:207-14.
40. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 2001;50:405-22.
41. Amir E, Seruga B, Kwong R, Tannock IF, Ocana A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? *European Journal of Cancer* 2012;48:385-8.
42. Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. *Cancer journal* 2009;15:379-85.
43. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. *Neuro-oncology* 2010;12:274-82.

44. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. *Neuro-oncology* 2007;9:29-38.
45. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. *Cancer* 2001;91:2033-8.
46. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology 2007;25:4562-8.
47. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology 2007;25:5218-24.
48. Hotta K, Fujiwara Y, Matsuo K, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. *Journal of thoracic oncology* : official publication of the International Association for the Study of Lung Cancer 2009;4:311-7.
49. Li X, Liu S, Gu H, Wang D. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. *Journal of Cancer Research & Clinical Oncology* 2012;138:1963-9.
50. Mandrekar SJ, Qi Y, Hillman SL, et al. Endpoints in phase II trials for advanced non-small cell lung cancer. *Journal of thoracic oncology* : official publication of the International Association for the Study of Lung Cancer 2010;5:3-9.
51. Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. *Clinical lung cancer* 2013;14:261-6.

52. Hotta K, Kiura K, Fujiwara Y, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. *PloS one* 2011;6:e26646.
53. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology 2008;26:1987-92.
54. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. *British journal of cancer* 2005;93:1215-21.
55. Miksad RA, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. *International journal of technology assessment in health care* 2008;24:371-83.
56. Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2010;117:324-9.
57. Sundar S, Wu J, Hillaby K, Yap J, Lilford R. A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. *Gynecologic Oncology* 2012;125:493-9.
58. Shitara K, Ikeda J, Yokota T, et al. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. *Investigational New Drugs* 2012;30:1224-31.
59. Foster NR, Qi Y, Shi Q, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. *Cancer* 2011;117:1262-71.
60. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate

- cancer. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology 2009;27:2766-71.
61. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. *Cancer* 2011;117:2637-42.
62. Delea TE, Khuu A, Heng DYC, Haas T, Soulieres D. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. *British journal of cancer* 2012;107:1059-68.
63. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;17:2815-34.
64. Buyse M, Sargent DJ, Saad ED. Survival is not a good outcome for randomized trials with effective subsequent therapies. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology 2011;29:4719-20; author reply 20-1.
65. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. *Annals of oncology* : official journal of the European Society for Medical Oncology / ESMO 2010;21:7-12.
66. Ciani O, Taylor RS. A more evidence based approach to the use of surrogate end points in policy making. *BMJ (Clinical research ed)* 2011;343:d6498.